Xin Liu

Xin Liu

Auto-generated profile, based on publicly available information

Xin Liu

Faculty of Health Medicine and Behavioural Science, University of Queensland Centre for Clinical Research, Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Critical Care Medicine
Verified
Journal Article
Closed access
DRDarren M. Roberts
Darren M. Roberts
JRJason Roberts
Jason Roberts
Michael RobertsMichael Roberts
Michael Roberts
XLXin Liu
Xin Liu
PNPriya Nair
Priya Nair
RBRinaldo Bellomo
Rinaldo Bellomo
In critically ill patients receiving continuous renal replacement therapy, we aimed to assess the variability of antibiotic trough concentrations, the influence of effluent flow rates on such concentrations, and the incidence of suboptimal antibiotic dosage. Prospective, observational, multicenter, pharmacokinetic study. Four tertiary intensive care units within the multicenter RENAL randomized controlled trial of continuous renal replacement therapy intensity. Twenty-four critically ill adult patients with acute kidney injury receiving ciprofloxacin, meropenem, piperacillin/tazobactam, or vancomycin during continuous renal replacement therapy. We obtained trough blood samples and measured antibiotic concentrations. We obtained data from 40 dosing intervals and observed wide variability in trough concentrations (6.7-fold for meropenem, 3.8-fold for piperacillin, 10.5-fold for tazobactam, 1.9-fold for vancomycin, and 3.9-fold for ciprofloxacin). The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8–18.4), 105.0 (74.4–204.0)/3.8 (3.4–21.8) for piperacillin/tazobactam, 12.0 (9.8–16.0) for vancomycin, and 3.7 (3.0–5.6) for ciprofloxacin. Overall, 15% of dosing intervals did not meet predetermined minimum therapeutic target concentrations, 40% did not achieve the higher target concentration, and, during 10% of dosing intervals, antibiotic concentrations were excessive. No difference, however, was found between patients on the basis of the intensity of continuous renal replacement therapy; this effect may have been obscured by differences in dosing regimens, time off the filter, or altered pharmacokinetics. There is significant variability in antibiotic trough concentrations in critically ill patients receiving continuous renal replacement therapy, which did not only appear to be influenced by effluent flow rate. Here, empirical dosing of antibiotics failed to achieve the target trough antibiotic concentration during 25% of the dosing intervals.

10 December 2014 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
HWHaolu Wang
Haolu Wang
CTCamilla A. Thorling
Camilla A. Thorling
XLXiaowen Liang
Xiaowen Liang
KBKim R. Bridle
Kim R. Bridle
JGJeffrey Grice
Jeffrey Grice
Michael RobertsMichael Roberts
Michael Roberts
Liver diseases, particularly viral hepatitis, cirrhosis and hepatocellular carcinoma, are common in clinical practice with high morbidity and mortality worldwide. Many substances for diagnostic imaging and therapy of liver diseases may have either severe adverse effects or insufficient effectiveness in vivo because of their nonspecific uptake. Therefore, by targeting the delivery of drugs into the liver or specific liver cells, drug efficiency may be largely improved. This review summarizes the up-to-date research progress focusing on nanoparticles targeting the liver for both diagnostic and therapeutic purposes. Targeting strategies, mechanisms of enhanced effects, and clinical applications of nanoparticles are discussed specifically. We believe that new targeting nanotechnology such as nanoprobes for multi-modality imaging and multifunctional nanoparticles would facilitate significant advancements in this active research area in the near future.

1 December 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
DRDarren M Roberts
Darren M Roberts
XLXin Liu
Xin Liu
JRJason Roberts
Jason Roberts
PNPriya Nair
Priya Nair
LCLouise Cole
Louise Cole
OIOn behalf of the RENAL Replacement Therapy Study Investigators
On behalf of the RENAL Replacement Therapy Study Investigators
Introduction: Continuous renal replacement therapy (CRRT) may alter antibiotic pharmacokinetics and increase the risk of incorrect dosing. In a nested cohort within a large randomized controlled trial, we assessed the effect of higher (40 mL/kg per hour) and lower (25 mL/kg per hour) intensity CRRT on antibiotic pharmacokinetics. Methods: We collected serial blood samples to measure ciprofloxacin, meropenem, piperacillin-tazobactam, and vancomycin levels. We calculated extracorporeal clearance (CL), systemic CL, and volume of distribution (Vd) by non-linear mixed-effects modelling. We assessed the influence of CRRT intensity and other patient factors on antibiotic pharmacokinetics. Results: We studied 24 patients who provided 179 pairs of samples. Extracorporeal CL increased with higher-intensity CRRT but the increase was significant for vancomycin only (mean 28 versus 22 mL/minute; P = 0.0003). At any given prescribed CRRT effluent rate, extracorporeal CL of individual antibiotics varied widely, and the effluent-to-plasma concentration ratio decreased with increasing effluent flow. Overall, systemic CL varied to a greater extent than Vd, particularly for meropenem, piperacillin, and tazobactam, and large intra-individual differences were also observed. CRRT dose did not influence overall (systemic) CL, Vd, or half-life. The proportion of systemic CL due to CRRT varied widely and was high in some cases. Conclusions: In patients receiving CRRT, there is great variability in antibiotic pharmacokinetics, which complicates an empiric approach to dosing and suggests the need for therapeutic drug monitoring. More research is required to investigate the apparent relative decrease in clearance at higher CRRT effluent rates. Trial registration: ClinicalTrials.gov NCT00221013. Registered 14 September 2005.

13 January 2016 in ACS Nano
Verified
Journal Article
Closed access
XLXiaowen Liang
Xiaowen Liang
HWHaolu Wang
Haolu Wang
YZYian Zhu
Yian Zhu
Run ZhangRun Zhang
Run Zhang
VCVictoria C. Cogger
Victoria C. Cogger
Michael RobertsMichael Roberts
Michael Roberts

22 September 2009 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SHS. He
S. He
XLX. Liu
X. Liu
YYYan Yang
Yan Yang
WHW. Huang
W. Huang
SXS. Xu
S. Xu
Michael RobertsMichael Roberts
Michael Roberts

23 May 2011 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
XLXin Liu
Xin Liu
JGJeff E. Grice
Jeff E. Grice
JLJuergen Lademann
Juergen Lademann
NONina Otberg
Nina Otberg
STSindy Trauer
Sindy Trauer
Michael RobertsMichael Roberts
Michael Roberts
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Depending on the body site and the substances, the hair follicles can contribute significantly to the penetration of topically applied substances. However, the quantitative and selective description of the follicular and intercellular penetration kinetics is difficult due to the lack of suitable models to differentiate between the different penetration pathways. Recently, for the first time, the follicular transport was measured directly in man in vivo indicating that the hair follicles are responsible for a fast delivery of topically applied substances.WHAT THIS STUDY ADDS• In the present study, pharmacokinetic principles were applied to define the underlying relative penetration of caffeine through follicles and through intact stratum corneum with time in vivo. Absorption from hair follicles was found to contribute more than one third of the total percutaneous absorption of caffeine. Additionally, it was observed that the uptake by the hair follicles appeared at early times and was transient.AIMS The aim of this study was to define the underlying relative penetration of caffeine through hair follicles and through intact stratum corneum with time in vivo through pharmacokinetic modelling.METHODS Caffeine plasma concentration–time profiles after topical application into skin with or without hair follicle blocking were modelled using the Wagner–Nelson method or a compartmental model with first order absorption and elimination. Pharmacokinetic parameters describing absorption rate and extent of absorption through hair follicles or the stratum corneum were determined separately and compared with each other.RESULTS The obtained pharmacokinetic parameters from the two methods were similar. The absorption rate constant of caffeine for hair follicles was nearly 10 times higher than that for the stratum corneum and the percentage of absorption from hair follicles was more than half of that of the stratum corneum. In addition, the absorption from the stratum corneum showed an approximately 10 min delay while there was no delay for absorption from hair follicles. All caffeine absorbed by hair follicles occurs within 30 min of application and accounts for 10.5 to 33.8% of the total amount absorbed across the skin for all subjects, whereas absorption of caffeine through the stratum corneum can occur over several hours.CONCLUSION Hair follicles contribute significantly to percutaneous absorption of caffeine after topical application in man in vivo only at times soon after application.